NVAX - Company ID 0001000694
NOVAVAX INC (NVAX) reported revenue of $1.12B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $1.12B | +64.7% |
| FY 2024 | $682.16M | -30.7% |
| FY 2023 | $983.71M | -50.4% |
| FY 2022 | $1.98B | +72.9% |
| FY 2021 | $1.15B | +141.0% |
| FY 2020 | $475.60M | +2448.5% |
| FY 2019 | $18.66M | -45.6% |
| FY 2018 | $34.29M | +10.0% |
| FY 2017 |
NOVAVAX INC (NVAX) reported revenue of $1.12B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, NOVAVAX INC's revenue grew from $14.69M to $1.12B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $31.18M |
| +103.1% |
| FY 2016 | $15.35M | -57.6% |
| FY 2015 | $36.25M | +18.2% |
| FY 2014 | $30.66M | +46.6% |
| FY 2013 | $20.91M | -5.3% |
| FY 2012 | $22.08M | +50.3% |
| FY 2011 | $14.69M | - |